GSK has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly surpassing market expectations. The fourth quarter contributed £8.1 billion, a 4% rise ...

Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and ...

The pharmaceutical company citied promising pipeline developments and said cancer treatments drove above-expected growth.

Final investment decisions had been made for the Tarbert Next (LON: NXT) Generation biopower station in Co Kerry and the ...

Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product DevelopmentTonix is Preparing for Potential Launch ...

Shares of GSK plc (NYSE:GSK – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. Six ...

Ballentine Partners LLC boosted its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 40.7% in the fourth quarter, ...

European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...

As the company faces criticism for its decision last year to not renew insurance policies for 72,000 property owners in California, State Farm has nixed plans to run a commercial during this year ...

GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare Conference, the European healthcare giant noted there ...

GSK started this year’s J.P. Morgan Healthcare ... adding that IDRx has all the characteristics he and Chief Commercial Officer Luke Miels look for in business deals. “It's got an interesting ...